Page 84 - Read Online

García-Pardo et al. J Cancer Metastasis Treat 2021;7:62 https://dx.doi.org/10.20517/2394-4722.2021.103 Page 21 of 22

119. Liu Y, Shi K, Chen Y, et al. Exosomes and their role in cancer progression. Front Oncol 2021;11:639159. DOI PubMed PMC
120. Paggetti J, Haderk F, Seiffert M, et al. Exosomes released by chronic lymphocytic leukemia cells induce the transition of stromal cells
into cancer-associated fibroblasts. Blood 2015;126:1106-17. DOI PubMed PMC
121. Ghosh AK, Secreto CR, Knox TR, Ding W, Mukhopadhyay D, Kay NE. Circulating microvesicles in B-cell chronic lymphocytic
leukemia can stimulate marrow stromal cells: implications for disease progression. Blood 2010;115:1755-64. DOI PubMed PMC
122. Nisticò N, Maisano D, Iaccino E, et al. Role of chronic lymphocytic leukemia (cll)-derived exosomes in tumor progression and
survival. Pharmaceuticals (Basel) 2020;13:244. DOI PubMed PMC
123. Yeh YY, Ozer HG, Lehman AM, et al. Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced
secretion by activation of BCR signaling. Blood 2015;125:3297-305. DOI PubMed PMC
124. Ferrajoli A, Shanafelt TD, Ivan C, et al. Prognostic value of miR-155 in individuals with monoclonal B-cell lymphocytosis and
patients with B chronic lymphocytic leukemia. Blood 2013;122:1891-9. DOI PubMed PMC
125. Farahani M, Rubbi C, Liu L, Slupsky JR, Kalakonda N. CLL exosomes modulate the transcriptome and behaviour of recipient
stromal cells and are selectively enriched in miR-202-3p. PLoS One 2015;10:e0141429. DOI PubMed PMC
126. Prieto D, Sotelo N, Seija N, et al. S100-A9 protein in exosomes from chronic lymphocytic leukemia cells promotes NF-κB activity
during disease progression. Blood 2017;130:777-88. DOI PubMed
127. Geng HY, Feng ZJ, Zhang JJ, Li GY. Exosomal CLIC1 released by CLL promotes HUVECs angiogenesis by regulating ITGβ1-
MAPK/ERK axis. Kaohsiung J Med Sci 2021;37:226-35. DOI PubMed
128. Crompot E, Van Damme M, Pieters K, et al. Extracellular vesicles of bone marrow stromal cells rescue chronic lymphocytic
leukemia B cells from apoptosis, enhance their migration and induce gene expression modifications. Haematologica 2017;102:1594-
604. DOI PubMed PMC
129. Till KJ, Spiller DG, Harris RJ, Chen H, Zuzel M, Cawley JC. CLL, but not normal, B cells are dependent on autocrine VEGF and
alpha4beta1 integrin for chemokine-induced motility on and through endothelium. Blood 2005;105:4813-9. DOI PubMed
130. Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat Rev Mol Cell Biol 2014;15:786-
801. DOI PubMed PMC
131. García-pardo A, Opdenakker G. Nonproteolytic functions of matrix metalloproteinases in pathology and insights for the development
of novel therapeutic inhibitors. Metalloproteinases Med 2015;2:19-28. DOI
132. Bailón E, Aguilera-Montilla N, Gutiérrez-González A, et al. A catalytically inactive gelatinase B/MMP-9 mutant impairs homing of
chronic lymphocytic leukemia cells by altering migration regulatory pathways. Biochem Biophys Res Commun 2018;495:124-30.
DOI PubMed
133. Vaisitti T, Serra S, Pepper C, et al. CD38 signals upregulate expression and functions of matrix metalloproteinase-9 in chronic
lymphocytic leukemia cells. Leukemia 2013;27:1177-81. DOI PubMed
134. Lee YK, Bone ND, Strege AK, Shanafelt TD, Jelinek DF, Kay NE. VEGF receptor phosphorylation status and apoptosis is
modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia. Blood
2004;104:788-94. DOI PubMed
135. Lee YK, Shanafelt TD, Bone ND, Strege AK, Jelinek DF, Kay NE. VEGF receptors on chronic lymphocytic leukemia (CLL) B cells
interact with STAT 1 and 3: implication for apoptosis resistance. Leukemia 2005;19:513-23. DOI PubMed
136. Pepper C, Ward R, Lin TT, et al. Highly purified CD38+ and CD38- sub-clones derived from the same chronic lymphocytic leukemia
patient have distinct gene expression signatures despite their monoclonal origin. Leukemia 2007;21:687-96. DOI PubMed
137. Farahani M, Treweeke AT, Toh CH, et al. Autocrine VEGF mediates the antiapoptotic effect of CD154 on CLL cells. Leukemia
2005;19:524-30. DOI PubMed
138. Avraamides CJ, Garmy-Susini B, Varner JA. Integrins in angiogenesis and lymphangiogenesis. Nat Rev Cancer 2008;8:604-17. DOI
PubMed PMC
139. König A, Menzel T, Lynen S, et al. Basic fibroblast growth factor (bFGF) upregulates the expression of bcl-2 in B cell chronic
lymphocytic leukemia cell lines resulting in delaying apoptosis. Leukemia 1997;11:258-65. DOI PubMed
140. Bairey O, Zimra Y, Shaklai M, Rabizadeh E. Bcl-2 expression correlates positively with serum basic fibroblast growth factor (bFGF)
and negatively with cellular vascular endothelial growth factor (VEGF) in patients with chronic lymphocytic leukaemia. Br J
Haematol 2001;113:400-6. DOI PubMed
141. Romanov VV, James CH, Sherrington PD, Pettitt AR. Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells
of a proportion of patients with chronic lymphocytic leukaemia. Oncogene 2005;24:6855-60. DOI PubMed
142. Martinez-Torres AC, Quiney C, Attout T, et al. CD47 agonist peptides induce programmed cell death in refractory chronic
lymphocytic leukemia B cells via PLCγ1 activation: evidence from mice and humans. PLoS Med 2015;12:e1001796. DOI PubMed
PMC
143. Ringshausen I, Dechow T, Schneller F, et al. Constitutive activation of the MAPkinase p38 is critical for MMP-9 production and
survival of B-CLL cells on bone marrow stromal cells. Leukemia 2004;18:1964-70. DOI PubMed
144. Condoluci A, Rossi D. Richter syndrome. Curr Oncol Rep 2021;23:26. DOI PubMed PMC
145. Kohlhaas V, Blakemore SJ, Al-Maarri M, et al. Active Akt signaling triggers CLL toward Richter transformation via overactivation
of Notch1. Blood 2021;137:646-60. DOI PubMed
146. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and
rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol 2005;23:4079-88. DOI PubMed
147. Molica S, Vacca A, Tucc L, Ribatti D. Reversal of bone marrow angiogenesis in chronic lymphocytic leukemia following fludarabine
therapy. Haematologica 2005;90:698-700. PubMed